Serpentine supravenous hyperpigmentation – A rare cutaneous manifestation in non-neoplastic conditions

Serpentine supravenous hyperpigmentation

Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. The lesions gradually resolve spontaneously if administration of the offending agent is stopped through the affected limb. Drugs such as 5-fluorouracil, docetaxel, vinorelbine, hydroxychloroquine, fotemustine, and minocycline are impl...

Serpentine supravenous hyperpigmentation following cisplatin and pemetrexed chemotherapy.

E20 CUTIS WWW.CUTIS.COM To the Editor: Serpentine supravenous hyperpigmentation (SSH) is a rare phenomenon characterized by linear hyperpigmentation of the skin overlying veins secondary to intravenous antineoplastic therapy. The term was first suggested by Hrushesky1 in 1976 as an uncommon side effect of administering intravenous 5-fluorouracil (5-FU). Although 5-FU is the most frequent offend...

Chemotherapy-associated supravenous hyperpigmentation.

Reversible generalized cutaneous hyperpigmentation: presenting manifestation of pernicious anemia.

A 16-year-old boy presented with progressive and asymptomatic mottled hyperpigmentation that had been there for four years. The lesions had appeared initially on his arms and extended gradually over the years to involve the trunk, face, and extremities (Fig. 1). The palms and soles were prominently involved, and fingernails showed longitudinal hyperpigmented streaks (Fig. 2). The mucous membran...

Persistent serpentine supravenous hyperpigmented eruption in lepromatous leprosy after minocycline.

Persistent serpentine supravenous hyperpigmented eruption (PSSHE) is a peculiar patterned eruption characterised by hyperpigmented streaks following the superficial venous network on the skin. Unlike the superficial thrombophlebitis, it is characterised by underlying vessels that are patent. It has been described most commonly after injection of chemotherapeutic drugs. We describe a 40 year old...